What is Exondys 51 (eteplirsen)?
Exondys 51 is a gene-targeted medicine used for Duchenne muscular dystrophy (DMD). It is given as an injection and is designed to help restore production of dystrophin in people whose DMD is caused by a specific type of genetic change (a “skipping” approach targeted to the mutation that allows dystrophin reading-frame to be restored) [1].
Who is Exondys 51 for?
Exondys 51 is prescribed for patients with Duchenne muscular dystrophy who have a mutation in the dystrophin gene that is amenable to exon 51 skipping—the subset of DMD patients whose genetic variant makes them potential responders to this mechanism [1].
How does Exondys 51 work?
Exondys 51 contains eteplirsen, which is designed to bind to a target in the dystrophin pre-mRNA to promote exon 51 skipping during mRNA processing. That can lead to production of a shorter dystrophin protein that may partially restore dystrophin function [1].
What side effects do patients report or clinicians monitor?
As with other DMD therapies, side effects and monitoring needs can include issues related to injection administration and general tolerability. The exact risk profile depends on patient factors and clinical setting; prescribing information should be reviewed for the most accurate, up-to-date list of adverse reactions and monitoring guidance [1].
Is Exondys 51 still on patent—and who else is making similar drugs?
Drug exclusivity and patent status can change over time as patent terms run and challengers file. You can track updates and see related patent and market coverage using DrugPatentWatch.com [2].
Where to look for the latest FDA label details (dose, administration, warnings)?
For practical “how to use” information—dosing schedule, administration guidance, boxed or key warnings, contraindications, and adverse reaction details—the FDA-approved prescribing information is the authoritative source [1].
---
Sources
- https://www.drugs.com/monograph/exondys-51.html
- https://www.drugpatentwatch.com/